Warfarin antithrombotics
systematic review meta-analysis network meta-analysis
 

     

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome  

Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative∞%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
ATACS, 1994   warfarincontrol (on top of aspirin)negative∞%
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative

acute myocardial infarction  

Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative 150%-67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting 123%-5%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting3%∞%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting 232%-2%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 45%3%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting9%-27%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting∞%-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 309%3%

atrial fibrillation  

BAATAF (warfarin vs no treatment), 1990    NCTwarfarin low dosecontrolRisk of bias suggesting 96%-58%
SAFT(warfarin low dose + aspirin vs no treatment), 2003     warfarin low dose + aspirincontrolRisk of bias negative -14%
AFASAK (warfarin standard dose vs control), 1989   warfarin standard dosecontrolRisk of bias suggesting∞%
SPAF (warfarin standard dose), 1991   warfarin standard dosecontrolRisk of bias suggesting0%-25%
SPINAF (warfarin vs placebo), 1992   warfarin low doseplaceboLow risk of bias negative
CAFA, 1991   warfarin standard doseplaceboLow risk of bias negative411%
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998     warfarin + aspirinwarfarin standard doseRisk of bias negative
SPAF III, 1996   warfarin + aspirinwarfarin standard doseRisk of bias remark
MWNAF, 1998     warfarin low dosewarfarin standard doseRisk of bias negative
AFASAK II (warfarin low dose vs warfarin standard dose), 1998     warfarin low dosewarfarin standard doseRisk of bias negative

cardiovascular prevention  

Thrombosis Prevention trial (Warfarin), 1998        NCTwarfarinplaceboprimary preventionLow risk of bias suggesting -17%
Thrombosis Prevention trial (W plus A), 1998        NCTwarfarin + aspirinplaceboprimary preventionLow risk of bias suggesting -7%

heart failure  

WASH (warfarin), 2004     warfarinno treatmentnegative∞%17%
HELAS (warfarin vs placebo), 2006   warfarinplaceboLow risk of bias -
Barzizza (warfarin), 1993   warfarinplacebo -
HELAS (warfarin vs aspirin), 2006   warfarinaspirinLow risk of bias -
WATCH (warfarin vs aspirin), 2009      NCTwarfarinaspirinsuggesting43%-5%

peripheral vascular diseases  

Johnson, 2002   warfarincontrôle -
Sarac, 1998   warfarincontrôle -

post myocardial infarction  

APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting3%∞%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative 150%-67%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting 232%-2%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 45%3%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting 123%-5%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting9%-27%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%2%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting∞%-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 309%3%

post stroke  

SWAT, 1998   warfarinaspirinnegative

thrombosis prevention  

Pinto, 1970   Warfarinno treatment -
Hume, 1973   Warfarinno treatment -
Morris, 1976     Warfarinno treatment -
Powers, 1989   Warfarinno treatment -
Myrhe, 1969   WarfarinplaceboLow risk of bias -
Heit, 1997   WarfarinArdeparinLow risk of bias suggesting-88%-100%
RD Heparin, 1994   WarfarinArdeparinsuggesting-53%∞%
Powers, 1989   WarfarinAspirin -
Lotke, 1997     WarfarinAspirin -
Hull, 2000     WarfarinDalteparinLow risk of bias suggesting -71%101%
Francis, 1997     WarfarinDalteparinsuggesting-34%
van Comp, 1998   WarfarinDanaparoid -
Gerhart, 1991   WarfarinDanaparoid -
Francis, 1983   WarfarinDextran -
Harris, 1972   WarfarinDextran -
Myrhe, 1969   WarfarinDextranLow risk of bias -
Barber, 1977   WarfarinDextran -
Fitzgerald, 2001     WarfarinEnoxaparinsuggesting -56%195%
Colwell, 1999     WarfarinEnoxaparinsuggesting-56%13%
Leclerc, 1996     WarfarinEnoxaparinLow risk of bias suggesting-14%1%
Bailey, 1991   WarfarinIntermittent pneumatic compression -
Paiement, 1987   WarfarinIntermittent pneumatic compression -
Kaempffe, 1991     WarfarinIntermittent pneumatic compression -
Francis, 1992   WarfarinIntermittent pneumatic compression -
Hull, 1993     WarfarinLogiparinLow risk of bias suggesting-55%-8044%
Hume, 1973   WarfarinSudoxicam -
Barber, 1977   Warfarinunfractionated heparin -
Hume, 1973   Warfarinunfractionated heparin -

venous thrombosis  

Schulman, 1995     6 months1.5 monthssuggesting388%-25%
Pinede, 2001     3-6 months1.5-3 monthsnegative73%32%
Wells (subgroup), 2005     tinzaparindalteparinnegative-54%16%
DURAC (Schulman), 1997     warfarindiscontinuationsuggesting219%-40%
Agnelli, 2001     warfarindiscontinuationnegative99%-1%
Agnelli, 2003     warfarindiscontinuationnegative193%67%
LAFIT (Kearon), 1999       warfarindiscontinuationsuggesting∞%-65%
PREVENT (Ridker), 2003     warfarindiscontinuationsuggesting148%-50%
Levine, 1995   warfarindiscontinuationLow risk of bias suggesting∞%-4%
ELAET (Kearon), 2004     warfarindiscontinuationLow risk of bias negative∞%
PROLONG (Palareti), 2006      NCTwarfarindiscontinuationsuggesting∞%17%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons